Bill Meury, Karuna Therapeutics CEO
March 20, 2023 06:30 AM EDTUpdated 07:08 AM
R&D

Karuna’s schiz­o­phre­nia drug clears an­oth­er PhI­II as biotech seeks 2024 launch

Kyle LaHucik

Senior Reporter

Karuna Ther­a­peu­tics said its in­ves­ti­ga­tion­al schiz­o­phre­nia treat­ment cleared the bar in an­oth­er Phase III clin­i­cal tri­al, which the biotech hopes will open the doors for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times